Protein-truncating variants in RAD51C predispose to high-grade serous ovarian cancer (HGSOC) and triple-negative (TN) breast cancer (BC), and when these cancers occur in carriers of truncating variants they exhibit biallelic inactivation1–3. Here, RAD51C is linked to breast carcinoma.